Immunex Corporation

Amgen Inc.

Dirk E Smith

John Ernest Sims

Ian Nevin Foltz

Chadwick Terence King

Randal Robert Ketchem

Ai Ching Lim

Zhulun Wang

Xiaoshan Min

Rutilio Clark

Donghui Shi

Michael R Comeau

Teresa L Born

Jeffrey T McGrew

Marek Z Kubin

Louise Conroy

Duncan James Cochrane

Duncan Cochrane

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

ST2 antigen binding proteins

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.

Methods of treatment using IL-18 receptor antigen binding proteins

IL-18 receptor antigen binding proteins

The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.

Human IL-1 epsilon DNA and polypeptides

The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.

IL-1 zeta splice variant polypeptide

DNA encoding IL-1R AcP splice variant polypeptides, the polypeptides and methods for using the encoded polypeptides are disclosed.

IL-1 receptor accessory protein

The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening for agonists or antagonists of IL-1 epsilon activity, and kits comprising such polypeptides.

Methods of treating inflammatory and/or autoimmune disease

Polynucleotide encoding IL-1 zeta, TDZ.1 isoform polypeptide

DNA encoding IL-1 receptor accessory protein

Polynucleotide encoding IL-1 zeta polypeptide

Growing community of inventors

Bainbridge Island, WA, United States of America

Dirk E Smith